Dipeptidyl peptidase IV inhibitors for the treatment of diabetes.
about
Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberinePeptidomics of prolyl endopeptidase in the central nervous system.The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes.Expanding the dipeptidyl peptidase 4-regulated peptidome via an optimized peptidomics platform.Uric acid inhibition of dipeptidyl peptidase IV in vitro is dependent on the intracellular formation of triuretEmerging principles in protease-based drug discovery.Peptidomics of the prolyl peptidasesSitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.A substrate-free activity-based protein profiling screen for the discovery of selective PREPL inhibitors.SVMDLF: A novel R-based Web application for prediction of dipeptidyl peptidase 4 inhibitors.Sitagliptin/Metformin (janumet) as combination therapy in the treatment of type-2 diabetes mellitusInhibition of dipeptidylpeptidase IV activity as a therapy of type 2 diabetes.The role of vildagliptin in the management of type 2 diabetes mellitus.Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.Predicting the DPP-IV inhibitory activity pIC₅₀ based on their physicochemical properties.Renoprotective Effect of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Streptozotocin-Induced Type 1 Diabetic Mice.Berry and Citrus Phenolic Compounds Inhibit Dipeptidyl Peptidase IV: Implications in Diabetes ManagementPeptidase substrates via global peptide profiling.Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus.The importance of green chemistry in process research and development.Novel DPP-4 inhibitors against diabetes.MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis in ob/ob mice.Novel hydrazine derivatives as selective DPP-IV inhibitors: findings from virtual screening and validation through molecular dynamics simulations.Food protein-derived bioactive peptides in management of type 2 diabetes.Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).A novel hydroxyfuroic acid compound as an insulin receptor activator. Structure and activity relationship of a prenylindole moiety to insulin receptor activation.In vitro metabolism and transport of the new dipeptidyl peptidase 4 inhibitors, KR66222 and KR66223.Synthesis of a novel analogue of DPP-4 inhibitor Alogliptin: Introduction of a spirocyclic moiety on the piperidine ring.Improved enzymatic syntheses of valuable beta-arylalkyl-beta-amino acid enantiomers.Scalable synthesis of oxazolones from propargylic alcohols through multistep palladium(II) catalysis: β-selective oxidative Heck coupling of cyclic sulfonyl enamides and aryl boroxines.Phenotyping of congenic dipeptidyl peptidase 4 (DP4) deficient Dark Agouti (DA) rats suggests involvement of DP4 in neuro-, endocrine, and immune functions.Degradation of Incretins and Modulation of Blood Glucose Levels by Periodontopathic Bacterial Dipeptidyl Peptidase 4.Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes.One-pot high-yielding synthesis of the DPP4-selective inhibitor ABT-341 by a four-component coupling mediated by a diphenylprolinol silyl ether.Inhibitors of proline-specific dipeptidyl peptidases: DPP IV inhibitors as a novel approach for the treatment of Type 2 diabetes
P2860
Q28253310-881D3003-B659-42FA-85D9-514E34337910Q30884523-FE04B99B-9DEA-4C7F-9E51-A7654F552321Q33630394-230BEA96-9E77-4E60-AD22-7994B66E93FAQ33742666-C8418644-A8D9-40E3-87C6-DD692E3CA9D9Q33937015-28C98C65-81B3-412F-B5E6-47DEE3615444Q34282102-4B5B83E4-6D4E-463C-82CA-84C53C89269CQ34293605-CBA7EDB3-BB8F-4D8B-8CC9-8A97D8A02EBDQ34569365-737394F5-0480-4717-BFE0-2F9BC7A086D1Q35131941-6CB003CC-496F-4FB7-A1DE-823F896CB2CFQ36393746-20304FED-7761-404D-BE2C-85CFFB0ED7AAQ36523423-1D4363B1-DC40-4704-8936-8816F588BBD2Q36580608-8BB781F8-864A-4225-8772-4AC0B4D4918FQ36800624-F883BB41-F97F-4B85-953C-F17F003EFB45Q36892807-79F89669-ABA1-4C0A-BADF-E951F55C71E0Q36995316-B3F24005-5988-41AC-904D-517F9A7CAC39Q37056839-E3A6D6BF-329F-4259-8AF2-69A9EC9285EFQ37171907-19CF254D-CA36-43B0-B3C1-D0C7780F2273Q37313520-B3BDEEC7-80AF-44F0-ADC5-74AA1779DA67Q37735838-EB01E901-67D8-4F1D-8588-F31FA2173615Q37857691-467779F9-30AD-4609-B644-DEA17274C33EQ37874451-6D6FFE40-F191-45A4-A6D9-FD5B584A8B82Q38221278-6983F611-60F4-4507-B765-7948EDF568B4Q38302500-E45CEA5A-27FC-4279-9E00-707F0E511629Q38398676-D42A7BF4-0305-49C3-A24C-93BCA6D3D3FCQ38543982-098A21BF-B196-41D1-8415-95E0BFCA8F98Q38669170-492B5850-54B2-4BB5-A22D-55FB56EED2A5Q39535230-99129AC4-7237-4037-ABA5-8702AEC45838Q42484308-7C591749-616B-40F4-9566-97860BFE798DQ42549578-D53C5A2F-4AF7-47A9-ABB6-7D18630AA2D7Q43172235-C0DA7EB7-E6A8-49AA-BE41-6A0E9C0B5146Q45898409-1C8E945D-E9B0-4135-81D0-597A5CE789F0Q46071696-B0D92BB5-0B5E-4421-BA6B-D3EAABAE2BA8Q48255950-72E674DA-1438-40DC-B8B7-23BBD1CB3E44Q49598911-28274080-0DA6-4842-B51E-0BBD2AD1C73BQ54398666-25725433-3AE6-43EF-A71C-D22CFAE5F256Q58864225-ACF1B89E-DFF4-4819-9390-6C3D92A41940
P2860
Dipeptidyl peptidase IV inhibitors for the treatment of diabetes.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Dipeptidyl peptidase IV inhibitors for the treatment of diabetes.
@ast
Dipeptidyl peptidase IV inhibitors for the treatment of diabetes.
@en
type
label
Dipeptidyl peptidase IV inhibitors for the treatment of diabetes.
@ast
Dipeptidyl peptidase IV inhibitors for the treatment of diabetes.
@en
prefLabel
Dipeptidyl peptidase IV inhibitors for the treatment of diabetes.
@ast
Dipeptidyl peptidase IV inhibitors for the treatment of diabetes.
@en
P356
P1476
Dipeptidyl peptidase IV inhibitors for the treatment of diabetes.
@en
P2093
Ann E Weber
P304
P356
10.1021/JM030628V
P407
P577
2004-08-01T00:00:00Z